TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease with broad-reaching impact on public health that accounts for 15% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In 2014 in the United States alone it is estimated that the disease will culminate in 224,210 new cases and 159,260 deaths. Only 16% of all patients with lung cancer are alive 5 years or more after diagnosis, despite currently available therapies. Among the 15% of lung cancer cases diagnosed as early, localized disease, 5-year survival rates increase to approximately 53%. Thus, early detection and treatment of lung cancer remain important issues to researchers and clinicians alike, and oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and in the maintenance of patient physical and psychosocial well-being.

These video proceedings from the fourth part of a 6-part integrated CNE curriculum originally held at the 2014 ONS Annual Congress feature discussions with leading lung cancer investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lung cancer.

LEARNING OBJECTIVES

• Discuss the benefits and risks associated with systemic treatments used in the evidence-based treatment of metastatic non-small cell lung cancer (NSCLC), including chemotherapeutic agents and targeted biologic therapies.
• Communicate the clinical relevance of gene mutations and tumor histology to patients with NSCLC.
• Appreciate the recent FDA approvals of nanoparticle albumin-bound (nab) paclitaxel and afatinib for the management of NSCLC, and effectively integrate these agents into current treatment algorithms.
• Explain the relative risk of treatment-induced side effects to patients with NSCLC who are eligible to receive chemotherapy and bevacizumab.
• Educate patients receiving EGFR inhibitors about preventive and emergent strategies to reduce or ameliorate dermatotoxicity.
• Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with advanced NSCLC to improve clinical and quality-of-life outcomes.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

FOR SUCCESSFUL COMPLETION
This is a video CNE program. Participants should read the learning objectives and faculty disclosures and watch the video.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Geoffrey R Oxnard, MD
Assistant Professor of Medicine
Harvard Medical School
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: Aveo Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Honoraria: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd.

Karen L Reckamp, MD, MS
Associate Professor
Co-Director, Lung Cancer and Thoracic Oncology Program
City of Hope Comprehensive Cancer Center
Duarte, California

Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc; Consulting Agreement: Amgen Inc; Contracted Research: Astellas, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc.

Rebecca Lynn Sipples, MSN, APRN, ACNP, AOCNP
Yale University/Smilow Cancer Hospital
Thoracic Oncology Program — Oncology Nurse Practitioner
Yale School of Nursing — Faculty Lecturer
MGH Institute of Health Professions — DNP Student
New Haven, Connecticut

Speakers Bureau: Boehringer Ingelheim Pharmaceuticals Inc, Pfizer Inc.

Alison J Holmes Tisch, MSN, RN, ANP-BP, AOCNP
Stanford Cancer Institute
Stanford, California

No real or apparent conflicts of interest to disclose.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation and Genentech BioOncology.

Hardware/Software Requirements:
A high-speed Internet connection  
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.